Eyal C. Attar - Jun 3, 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SVP, Chief Medical Officer, Director
Signature
/s/ Scott M. Coiante, attorney-in-fact
Stock symbol
APRE
Transactions as of
Jun 3, 2022
Transactions value $
-$26,297
Form type
4
Date filed
6/7/2022, 05:00 PM
Previous filing
Mar 14, 2022
Next filing
Oct 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Tax liability -$26.3K -32.7K -36.34% $0.81* 57.2K Jun 3, 2022 Direct F1
holding APRE Common Stock 172 Jun 3, 2022 By adult child F2
holding APRE Common Stock 159 Jun 3, 2022 By adult child F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 89,900 restricted stock units.
F2 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.